News

Walmart, Target initiated: Wall Street's top analyst calls

US wholesale prices fell last month, new data showed Friday, an indication that inflationary pressures weren’t necessarily building before they reach the consumer.

JOHANNESBURG (Reuters) -Turmoil in the wake of U.S. President Donald Trump's tariff hikes has abruptly stalled emerging market sovereign debt sales in April, after issuance from developing nations and companies shattered first-quarter records. April is usually a busy month for emerging market debt sales on international capital markets, but policy uncertainty, fears of global recession and spiking U.S. yields have choked risk appetite. This is in sharp contrast to the first quarter, where emerging market firms issued $150 billion and sovereigns $89 billion, according to calculations from JPMorgan.

The Federal Reserve should intervene in markets only reluctantly and in a true emergency, Minneapolis Fed President Neel Kashkari said on Friday in the most explicit comments yet from a Fed official about responding to the volatility that has torn across markets in response to President Donald Trump's tariff barrage. "The Fed or Treasury stepping in should be done reluctantly, should be done when it is only truly needed," said Kashkari, who as a Treasury official during the 2007-09 financial crisis led the Troubled Asset Relief Program. "I think we should be very cautious about taking moves that could demonstrate a weakening, which I don't think is there, to the Fed's commitment to getting inflation down."

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 14.1%. This performance was worse than the S&P 500’s 9.3% decline.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.